An immediate intravesical instillation of mitomycin C is of benefit in all prognostic risk groups with non-muscle-invasive bladder cancers

A year ago, the largest and latest randomized clinical trial on immediate intravesical instillation with mitomycin C (MMC) in patients with non-muscle-invasive bladder cancer (NMIBC) was published (1) and was subject of an editorial in this journal (2). As suggested in that editorial, the trial has been reanalyzed to identify subgroups of NMIBC in which the treatment was not effective in prevention of recurrence (3).